

Faron Pharmaceuticals Oy
("Faron" or the "Company")

Faron Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

TURKU – FINLAND, March 11, 2021 – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present at the virtual Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 10:40 a.m. ET.

An audio webcast of the presentation will be available in the "Investors" section on Faron's website at <https://www.faron.com/investors>

ENDS

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in phase I/II clinical development as a potential therapy for patients with untreatable solid tumours, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalised patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Stern Investor Relations, Inc.

Julie Seidel

Phone: +(1)212 362 1200

Email: julie.seidel@sternir.com

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com